Age dependent prognosis in concurrent chemo-radiation of locally advanced NSCLC

References

• Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90.
   PubMed Web of Science ®Google Scholar
• O’Rourke N, Roque IF, Farre BN, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010;CD002140.
   Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lunge cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899–909.
   PubMed Web of Science ®Google Scholar
• Aridgides PD, Janik A, Bogart JA, Duffy S, Rosenbaum P, Gajra A. Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age >/ = 70 years). Clin Lung Cancer 2013;14:674–9.
   PubMed Web of Science ®Google Scholar
• Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: Analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012;23:1730–8.
   PubMed Web of Science ®Google Scholar
• Lee JH, Wu HG, Kim HJ, Kim DW, Lee SH, Kim TM, et al. Influence of comorbidities on the efficacy of radiotherapy with or without chemotherapy in elderly stage III non-small cell lung cancer patients. Cancer Res Treat 2012;44:242–50.
   PubMedGoogle Scholar
• Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, et al. Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 2011;6:537–44.
   PubMed Web of Science ®Google Scholar
• Schytte T, Nielsen TB, Brink C, Hansen O. Pattern of local failure in non-small cell lung cancer patients treated with definitive radiotherapy. Acta Oncol 2014;53:336–41.
   PubMed Web of Science ®Google Scholar
• Jeppesen SS, Schytte T, Jensen HR, Brink C, Hansen O. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: An updated retrospective study on local failure and survival rates. Acta Oncol 2013;52:1552–8.
   PubMed Web of Science ®Google Scholar
• Schytte T, Hansen O, Stolberg-Rohr T, Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol 2010;49:1058–60.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Hansen O, Vach W. Attempts to predict the long-term decrease in lung function due to radiotherapy of non-small cell lung cancer. Radiother Oncol 2006;78:165–8.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th ed (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803–4.
   Google Scholar
• Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the tnm stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706–14.
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Herndon II JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the cancer and leukemia group B. Cancer 2002;94:181–7.
   PubMed Web of Science ®Google Scholar
• Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:S70–6.
   PubMed Web of Science ®Google Scholar
• Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444–50.
   PubMed Web of Science ®Google Scholar
• Wanders R, Steevens J, Botterweck A, Dingemans AM, Reymen B, Baardwijk A, et al. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: A prospective population-based study. Eur J Cancer 2011;47:2691–7.
   PubMed Web of Science ®Google Scholar
• Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143: e314S–40S.
   Google Scholar
• Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: A randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13:671–8.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Hsu C, Curran WJ, Komaki R, Lee JS, Byhardt RB, et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Ann Meet Am Soc Clin Oncol 2002;21:299a (Abstract 1193).
   Google Scholar
• Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007;110:363–8.
   PubMed Web of Science ®Google Scholar
• Holgersson G, Hoye E, Bergqvist M, Ekman S, Nyman J, Helsing M, et al. Swedish Lung Cancer Radiation Study Group: Predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancer. Acta Oncol 2012;51:759–67.
   PubMed Web of Science ®Google Scholar
• Leprieur EG, Fernandez D, Chatellier G, Klotz S, Giraud P, Durdux C. Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: Clinical, dosimetric, and associated-treatment risk factors. J Cancer Res Ther 2013;9:447–51.
   PubMed Web of Science ®Google Scholar
• Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, et al. Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 2011;81:e269–74.
   PubMed Web of Science ®Google Scholar
• Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: A good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003;40: 79–84.
   PubMed Web of Science ®Google Scholar